Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 15 results
Filters: Author is Blood and Marrow Transplant Clinical Trials Network [Clear All Filters]
“Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012.”, Transplant Cell Ther, vol. 28, no. 7, pp. 406.e1-406.e6, 2022.
, “Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.”, Transplant Cell Ther, vol. 27, no. 10, pp. 879.e1-879.e3, 2021.
, “FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?”, J Clin Oncol, vol. 37, no. 19, pp. 1604-1607, 2019.
, “The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.”, Biol Blood Marrow Transplant, vol. 24, no. 7, pp. 1322-1340, 2018.
, “Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1108-1116, 2016.
, “Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ”, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
, “Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.”, J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.
, “A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.”, Lancet Haematol, vol. 2, no. 1, pp. e21-9, 2015.
, “One-unit versus two-unit cord-blood transplantation for hematologic cancers.”, N Engl J Med, vol. 371, no. 18, pp. 1685-94, 2014.
, “Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.”, Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.
, “Peripheral-blood stem cells versus bone marrow from unrelated donors.”, N Engl J Med, vol. 367, no. 16, pp. 1487-96, 2012.
, ,
“Graft-versus-host disease treatment: predictors of survival.”, Biol Blood Marrow Transplant, vol. 16, no. 12, pp. 1693-9, 2010.
, “Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.”, Blood, vol. 116, no. 24, pp. 5111-8, 2010.
,